Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer
29. Mai 2020 08:30 ET
|
Celsion CORP
Excellent Surgical Response Noted at the Higher, 100 mg/m2 Dose Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month...